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setting the reliability of a pre-release commercial algorithm 
for lung target volumes automatic segmentation for 
Stereotactic body radiation therapy (SBRT) and 4D radiation 
therapy (4DRT). 
Materials and Methods: 20 patients with histologically 
proven lung lesions between 2010 and 2014 (primitive or 
secondary) treated at our Institution with SBRT or 3D 
conformal Radiotherapy (3DCRT) were retrospectively 
collected. 
-13 patients with primary lung cancers or lung metastases (9 
patients with stage I lung cancer, 3 patients with lung 
metastases from rectal adenocarcinoma).  
-7 patients with locally-advanced-lung-cancer stage II-III were 
also selected to test the software with larger volumes. 
-Nodal Volumes were not taken into consideration 
Two Radiation Oncologists (RO) expert in lung cancers agreed 
the delineation of the lung lesions (Master Contour, MC). 
Two different RO performed the Automatic Delineation (AD) 
of the same lesions using the beta version of the 
SmartSegmentation-Knowledge-Based-Contouring 13.5, 
Varian Medical Systems. 
The 2 expert RO edited the automatic contour after a month, 
drawing Edited Delineation (ED). 
The obtained contours (AD and ED) were compared to MC. 
Comparisons were made in terms of geometrical overlap, by 
analyzing: 
Mean Dice-Similarity-Index (mDSI), Mean-Slicewise-Hausdorff-
Distances (MSHD) and Volume difference (cc). 
Results: The analysis of the contouring settings showed: 
1) MC vs AD: mean mDSI=0.78 (1SD±0.13); a MSHD=13.48mm 
(1SD±13.92) and a mean volume difference=4.06cc 
(1SD±18.94). 
2) MC vs ED mean mDSI=0.83 (SD±0.08); a MSHD=2.27mm 
(SD±3.39) and a mean volume difference=6.65cc (SD±18.89). 
When comparing the two groups a statistically significant 
greater concordance between MC vs ED than MC vs AD for DSI 
(p=0.0046) and for MSHD (p 
A qualitative analysis showed that for the early 
stages/metastases lesions qui lo leverei the software had a 
good performance (fig 1). The most significant differences 
between the 2 contours were have been observed at the lung 
bases, when lesions are close to the hepatic dome, and with 
hilum nodules due to structures isodensity. 
 
 
Conclusions: The tested autosegmentation software seems 
promising in the automatic delineation of lung lesions both 
for SBRT or 4DRT purposes and for 3DCRT in more advanced 
stages, offering an acceptable overlap with expert drawn 
contours, although human expert revision is always 
warranted. 
Investigations are ongoing on a larger number of patients to 
define a benchmark for early stage tumor/metastases and for 
locally advanced stages. 
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Purpose/Objective: The prognosis of patients with stage II-III 
non-small cell lung cancer (NSCLC) treated with concurrent 
chemoradiation (CCRT) remains poor. Tumour response 
monitoring over the course of CCRT with 18F-
fluorodeoxyglucose (FDG) PET/CT has the potential to adapt 
the radiation therapy plan to biological parameters. Frequent 
FDG PET/CT scanning, however, is associated with radiation 
exposure to the patient and personnel involved in daily 
treatment. We therefore designed and implemented a weekly 
PET/CT scan protocol using a low dose FDG. The aim of this 
evaluation concerned logistics, safety and patient burden of 
using weekly low dose FDG PET/CT during CCRT. 
Materials and Methods: Stage II-III NSCLC patients with no 
previous malignancies within the last 3 years, scheduled for 
24 x 2.75 Gy with daily low dose cisplatin, were eligible for 
inclusion. Five weekly PET/CT scans (Philips Gemini Big Bore 
ToF) of the tumour and regional lymph nodes in treatment 
position were made over the course of treatment (just before 
each fraction) and at 3 months after CCRT, each with 50 MBq 
FDG, a total scan time of 14 minutes, and two bed positions. 
The image quality of the PET/CT scans was evaluated visually 
and by signal-to-noise levels. The radiation exposure was 
assessed for patients and for staff. Finally, the logistics of 
the procedures in all involved departments was evaluated. 
Results: Thirteen patients were included of which ten 
completed the treatment and imaging course. A patient 
example is given in figure 1. One patient was excluded 
because a different radiotherapy scheme was chosen due to 
dose constraints, one patient demonstrated progressive 
disease on the PET/CT in week 1 and received altered 
treatment, and one patient found the extra imaging too 
demanding. The image quality of low dose FDG PET at 
baseline and during treatment was visually identical to 
routine diagnostic procedures, and had similar resolution and 
signal-to-noise levels. The radiation exposure of patients was 
about 20 mSv for the six scans in total. Following training on 
handling of radioactive patients in the departments of 
radiation oncology and medical oncology, involved staff did 
not receive a significant radiation dose (estimated < 1µSv per 
treatment). Planning logistics of 6 PET/CT scans linked to 
CCRT required close collaboration and dedicated imaging 
time slots. Patients typically spend 1.5 hours longer in 
hospital on days of PET/CT scans. 
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Conclusions: PET/CT with low dose FDG provides good image 
quality and is a promising method for frequent monitoring of 
tumour response during CCRT, with reduced imaging dose and 
cost relative to standard PET/CT. A multidisciplinary 
approach in protocol development and image acquisition is 
essential to derive safe and efficient workflows. 
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Purpose/Objective: Magnetic resonance imaging (MRI) is 
increasingly becoming the preferred modality for 
radiotherapy treatment planning (RTP) of oropharynx and 
larynx cancer due to its excellent soft tissue contrast. Two 
dimensional (2D) outlines of these cancer regions from 
sequential axial MRI slices restrict the view of cancer regions 
with respect to other anatomical structures. Three 
dimensional (3D) volume reconstruction of cancer from 
contiguous MRI slices help oncologists to understand the 
complex structure of cancer with a greater degree of 
certainty. 3D views allow oncologists to understand the 
geometry, margin and specific morphological features of 
cancer regions from different angles. In this work we use a 
novel Level Set based method to automatically reconstruct 
2D oropharynx and larynx cancer boundaries from real MRI 
slices, for 3D visualisation and subsequent quantification. 
Materials and Methods: Axial gadolinium-enhanced T1-
weighted (T1+Gd) MRI scans were obtained for 2 patients 
with pharyngeal cancer. Contours of cancer region from 12 
contiguous MRI slices of oropharynx cancer and 7 contiguous 
MRI slices of larynx cancer were obtained, using our new 
automatic processing method, and then compared to the 
contours defined manually by clinical experts. Information 
from DICOM header, such as slice location, slice thickness and 
spacing in between slices, is used to reconstruct cancer in 
3D. For this, each contour is sampled into uniformly spaced 
100 points. These contours are stacked to produce the 3D 
dataset. Furthermore 2 additional contours are inserted in-
between real contours using a conventional spline 
interpolation technique. 3D cancer region is reconstructed 
from these contours using rectangular mesh. 
Results: The agreement between manual and automatic 
contours was estimated by the dice similarity coefficient 
(DSC). The DSC for all 19 slices is shown in Table1. It can be 
observed that most slices have value greater than 0.75, 
except the first or last slices where cancer region is small, 
hence the DSC value is small. The average DSC value for 2 
patients is 0.82. Fig.1 shows the 3D view of oropharynx and 
larynx cancer regions. From Fig.1 it is clear that 3D 
reconstructed cancer region from automatic and manual 
contours are comparable. The average error between 
automatic volume and manual volume1 is 4.62% using manual 
volume1 as reference. This error is 9.52% between manual 
volume1 and manual volume2 using manual volume1 as 
reference. The tumor-cut technique developed in 2012 for 3D 
brain tumour segmentation from T1+Gd MRI demonstrates 
volume error of 5.7% for two best cases which is comparable 
with this automatic technique. 
Conclusions: This reconstruction tool produces smooth, 
acceptable 3D surface for cancerous regions. The 
reconstructed surfaces provide oncologists with additional 
information not easily available from simple 2D MRI slices, 
about cancer regions. It is anticipated that this will lead to 
improved RTP.  
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